Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.55 | 1.66 | -0.22 |
| FCF Yield | -8.16% | -11.88% | -8.36% | -2.46% |
| EV / EBITDA | -9.52 | -6.22 | -10.27 | -35.87 |
| Quality | ||||
| ROIC | 0.00% | -92.70% | -50.94% | -26.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.82 | 0.91 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 19.93% | -33.95% | -24.95% | -105.72% |
| Safety | ||||
| Net Debt / EBITDA | 2.02 | 0.32 | 0.34 | 3.13 |
| Interest Coverage | 181.29 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,306.13 | -14,760.60 |